Johnson & Johnson (JNJ) Stake Increased by Partnervest Advisory Services LLC
Partnervest Advisory Services LLC lifted its position in Johnson & Johnson (NYSE:JNJ) by 7.4% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,196 shares of the company’s stock after acquiring an additional 493 shares during the quarter. Partnervest Advisory Services LLC’s holdings in Johnson & Johnson were worth $952,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. New Jersey Better Educational Savings Trust grew its position in Johnson & Johnson by 5.3% during the second quarter. New Jersey Better Educational Savings Trust now owns 20,000 shares of the company’s stock valued at $2,646,000 after buying an additional 1,000 shares during the period. Davis Rea Ltd. grew its position in Johnson & Johnson by 1.1% during the second quarter. Davis Rea Ltd. now owns 4,790 shares of the company’s stock valued at $634,000 after buying an additional 50 shares during the period. Cadinha & Co. LLC grew its position in Johnson & Johnson by 0.5% during the second quarter. Cadinha & Co. LLC now owns 166,311 shares of the company’s stock valued at $22,001,000 after buying an additional 890 shares during the period. Schwab Charles Investment Management Inc. grew its position in Johnson & Johnson by 4.2% during the second quarter. Schwab Charles Investment Management Inc. now owns 11,623,639 shares of the company’s stock valued at $1,537,692,000 after buying an additional 473,300 shares during the period. Finally, Sigma Investment Counselors Inc. grew its position in Johnson & Johnson by 7.2% during the second quarter. Sigma Investment Counselors Inc. now owns 16,161 shares of the company’s stock valued at $2,138,000 after buying an additional 1,089 shares during the period. Hedge funds and other institutional investors own 65.61% of the company’s stock.
Several research firms recently weighed in on JNJ. Credit Suisse Group restated a “buy” rating on shares of Johnson & Johnson in a research report on Friday, August 4th. Piper Jaffray Companies restated a “hold” rating and set a $120.00 price target on shares of Johnson & Johnson in a research report on Wednesday, October 4th. Vetr downgraded shares of Johnson & Johnson from a “hold” rating to a “sell” rating and set a $130.49 price objective on the stock. in a report on Monday, September 18th. Stifel Nicolaus upped their price objective on shares of Johnson & Johnson from $140.00 to $142.00 and gave the company a “hold” rating in a report on Wednesday, October 18th. Finally, UBS AG reaffirmed a “buy” rating and set a $148.00 price objective on shares of Johnson & Johnson in a report on Thursday, August 31st. Four investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and eleven have given a buy rating to the company’s stock. Johnson & Johnson has a consensus rating of “Hold” and an average price target of $143.70.
ILLEGAL ACTIVITY NOTICE: This news story was originally posted by Watch List News and is the property of of Watch List News. If you are viewing this news story on another publication, it was stolen and republished in violation of United States and international copyright laws. The correct version of this news story can be viewed at https://www.watchlistnews.com/johnson-johnson-jnj-stake-increased-by-partnervest-advisory-services-llc/1723599.html.
Shares of Johnson & Johnson (JNJ) opened at $137.29 on Friday. Johnson & Johnson has a fifty-two week low of $109.32 and a fifty-two week high of $144.35. The stock has a market cap of $368,832.31, a PE ratio of 19.23, a PEG ratio of 2.79 and a beta of 0.82. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.32 and a quick ratio of 1.02.
Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, October 17th. The company reported $1.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.80 by $0.10. Johnson & Johnson had a net margin of 21.28% and a return on equity of 27.38%. The firm had revenue of $19.65 billion for the quarter, compared to the consensus estimate of $19.29 billion. During the same period in the prior year, the firm posted $1.68 earnings per share. The company’s revenue for the quarter was up 10.3% on a year-over-year basis. research analysts predict that Johnson & Johnson will post 7.28 EPS for the current year.
The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 12th. Stockholders of record on Tuesday, November 28th will be issued a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.45%. The ex-dividend date of this dividend is Monday, November 27th. Johnson & Johnson’s payout ratio is 58.33%.
Johnson & Johnson Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with Analyst Ratings Network's FREE daily email newsletter.